logo-loader
viewAdherium

Adherium builds on IPO with big pharma partnerships

au_medical_chart350_5612fa63c0a9d.jpg

Recent IPO Adherium (ASX:ADR) which boasts global biopharmaceutical company AstraZeneca as a cornerstone investor is making strides as the company’s Smartinhaler platform was lauded in paediatric asthma management in three independent studies.

In August, $35 million was raised by the New Zealand based company in an oversubscribed listing on the ASX.

The Sheffield study showed a substantial reduction in the need for oral steroids, indicating a significant reduction in severe attacks and an increase in lung function.

AstraZeneca is a commercial client and Adherium has a 10 year supply and development agreement with it, which is one of three partnerships with multinational pharmaceutical companies.

Adherium's SmartInhaler has been used in clinical trials in 29 countries. Its direct competitors are Propeller Health, Gecko Health Innovation and Cohero Health.

Adherium aims to address sub-optimal medication use in chronic disease and improve medication adherence for patients.

Adherium designs, manufactures and supplies health devices such as prescription tool Smartinhaler for people with respiratory diseases such as asthma. 

It tracks whether patients are adhering to their asthma medication schedules and sends the data to a smartphone app to enable better health and medicine management.

The IPO involved the quotation of 105 million shares at $0.50 per share. Last trade was $0.605.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Adherium

Price: 0.055 AUD

ASX:ADR
Market: ASX
Market Cap: $9.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Parkway Minerals focuses on technology after recent...

Parkway Minerals NL (ASX:PWN) executive director Bahay Ozcakmak updates Proactive on its recent acquisition of unlisted company Consolidated Potash Corporation, which gives Parkway an advanced stage potash project and ownership of an innovative brine processing technology. The executive...

6 hours, 37 minutes ago

2 min read